MedPath

A Clinical Trail of Venkara Parpam for Neerkattu Vatham (Benign Prostatic Hyperplasia)

Not yet recruiting
Conditions
Benign prostatic hyperplasia withlower urinary tract symptoms,
Registration Number
CTRI/2022/07/044050
Lead Sponsor
National Institute of Siddha
Brief Summary

Introduction

This is an open non randomized single arm, single centric clinical trial to

evaluate the effectiveness of venkara parpam in the management of neerkattu vatham (benign

prostatic hyperplasia) patients through International prostate symptom

score(IPSS),Prostate specific antigen(PSA) and Ulterasound sonography(USG) before

andafter treatment. Benign Prostatic Hyperplasia is a pathologic process that contributes

to the development of lower urinary tract symptoms in men. Such symptoms, arising from

lower urinary tract dysfunction, are further subdivided into voiding symptoms and

storage symptoms. BPH is one of the common diseases of the male community.

summarizing data from five prior studies showed that no men younger than 30 had

evidence of BPH. The prevalence of BPH accounts nearly 8% of men aged between 45

to 50 years, around 50% affected men aged those were between 50-80 years and in men

above 80 years of age the prevalence rate is almost 80%. An estimated 50% of men

demonstrate histopathologic BPH changes by age 60 years.. So my aim is to treat the

Neerkattu vatham(Benign Prostatic Hyperplasia) with the Siddha classical drug

VENKARA PARPAM.

MATERIALS AND METHODS:

A Total of 25 diagnosed patients of Neerkattu vatham(Benign Prostatic Hyperplasia)

within the age limit of 50 - 80 years willing to participate in the study ,by signing the

consent form will be enrolled in the study. CA Prostate,urinary bladder calculus,acute and

chronic renal failure,diabetic nephropathy,stricture urethra will be excluded. Assessment

in improvement is done through International prostate symptom score(IPSS),Prostate

specific antigen(PSA) and Ulterasound sonography(USG) before and after treatment.

RESULTS AND DISCUSSION:



The result will be statistically analyzed



KEYWORDS: Neerkattu vatham,Benign Prostatic Hyperplasia,Venkara Parpam

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
Male
Target Recruitment
25
Inclusion Criteria
  • Patients having symptoms such as delay in initiating micturition,hesitancy,weak urinary stream,straining to void,sensation of incomplete emptying and terminal dribbling.
  • Increased residual urine volume 3.
  • Nocturia ,urgency,bladder pain, dysuria 4.
  • PSA (Prostate specific antigen) less than 10ng/ml.
  • USG prostate volume not more than 80 cc.
Exclusion Criteria

KNOWN CASE OF CA prostate Urinary bladder calculus Acute and chronic renal failure Diabetic nephropathy Stricture urethra PSA more than 10 ng/ml USG prostate volume more than 80ml.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Assessment by clinical symptoms usingScreening - 2 months | Enrolment - 2 months | Drug - 4 months | Data analysis - 2 months | Follow up - 2 months
IPSS assessing scale.Screening - 2 months | Enrolment - 2 months | Drug - 4 months | Data analysis - 2 months | Follow up - 2 months
Secondary Outcome Measures
NameTimeMethod
1. To assess the changes in PSA Level2. To assess the reduction in size of the prostrate gland and prostrate volume and

Trial Locations

Locations (1)

Ayothidoss Pandithar Hospital

🇮🇳

Kancheepuram, TAMIL NADU, India

Ayothidoss Pandithar Hospital
🇮🇳Kancheepuram, TAMIL NADU, India
Dr C Selvalenin
Principal investigator
7639164757
leninselva555@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.